Published in J Cardiovasc Pharmacol on December 01, 1988
Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest (1998) 1.34
Intrarenal dopaminergic system regulates renin expression. Hypertension (2009) 1.17
Dopamine, the kidney, and hypertension. Curr Hypertens Rep (2012) 0.99
New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev (2012) 0.98
Lithium and the renal response to gludopa, fenoldopam and dopamine. Br J Clin Pharmacol (1990) 0.75
The potassium channel opener cromakalim (BRL 34915) activates ATP-dependent K+ channels in isolated cardiac myocytes. Biochem Biophys Res Commun (1988) 1.65
Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol (1974) 1.40
Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci U S A (1986) 1.25
Differential effects of prazosin on the pre- and postsynaptic alpha-adrenoceptors in the rat and dog [proceedings]. Br J Pharmacol (1977) 1.15
Effects of prazosin and phentolamine on cardiac presynaptic alpha-adrenoceptors in the cat, dog and rat. Clin Exp Hypertens (1978) 1.15
Studies on the mechanism of the vasodilator effects of prazosin in dogs and rabbits. Eur J Pharmacol (1978) 1.13
Cardiovascular effects of prazosin in dogs. Clin Sci Mol Med Suppl (1976) 1.09
Potassium channel openers act through an activation of ATP-sensitive K+ channels in guinea-pig cardiac myocytes. Pflugers Arch (1989) 1.07
Preliminary studies on SL 75212, a new potent cardioselective beta-adrenoceptor antagonist [proceedings]. Br J Pharmacol (1979) 1.06
The pharmacology of prazosin, a novel antihypertensive agent. Life Sci (1980) 1.03
Evidence for proteic water pathways in the luminal membrane of kidney proximal tubule. Biochim Biophys Acta (1986) 1.02
Cardiovascular characterization of DA-1 and DA-2 dopamine receptor agonists in anesthetized rats. Clin Exp Hypertens A (1987) 1.01
Urethane inhibits cardiovascular responses mediated by the stimulation of alpha-2 adrenoceptors in the rat. J Pharmacol Exp Ther (1982) 1.00
Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation (1992) 0.99
The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther (1991) 0.98
Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part I: Subclassification and functional description. Life Sci (1982) 0.95
K+ channel openers and 'natural' cardioprotection. Trends Pharmacol Sci (1992) 0.95
"Calcium antagonists": a class of drugs with a bright future. Part II. Determination of basic pharmacological properties. Life Sci (1984) 0.95
Vasodilator activity of endothelin-1 and endothelin-3: rapid development of cross-tachyphylaxis and dependence on the rate of endothelin administration. J Pharmacol Exp Ther (1990) 0.93
Cellular pharmacology of potassium channel openers in vascular smooth muscle. Cardiovasc Res (1994) 0.93
Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. J Pharmacol Exp Ther (1990) 0.93
The effects of prazosin on the clonidine induced hypotension and bradycardia in rats and sedation in chicks [proceedings]. Br J Pharmacol (1978) 0.92
Time-course analysis of the cardiovascular effects of clonidine resulting from the activation of cardiac pre- and vascular postsynaptic alpha-adrenoceptors in the pithed rat [proceedings]. Br J Pharmacol (1978) 0.92
Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol (1992) 0.91
Studies on the bradycardia induced by (-)- -trans-tetrahydrocannabinol in anesthetized dogs. Eur J Pharmacol (1973) 0.91
Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int (1988) 0.90
Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol. J Pharmacol Exp Ther (1987) 0.90
Systemic and regional hemodynamic characterization of alpha-1 and alpha-2 adrenoceptor agonists in pithed rats. J Pharmacol Exp Ther (1987) 0.89
"Calcium antagonists": a class of drugs with a bright future. Part I. Cellular calcium homeostasis and calcium as a coupling messenger. Life Sci (1983) 0.89
Effects of mianserin, desipramine and maprotiline on blood pressure responses evoked by acetylcholine, histamine and 5-hydroxytryptamine in rats. Br J Pharmacol (1981) 0.89
Studies on the rebound hypertension after clonidine withdrawal in conscious hypertensive cats, rats, and dogs [proceedings]. Br J Pharmacol (1977) 0.89
High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation. Mol Pharmacol (1988) 0.89
Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics. Fundam Clin Pharmacol (2000) 0.88
Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension (1980) 0.88
Role of cGMP as second messenger of adenosine in the inhibition of renin release. Kidney Int (1988) 0.88
Nicorandil: differential contribution of K+ channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin. J Pharmacol Exp Ther (1991) 0.88
Dietary salt intake modulates angiotensin II type 1 receptor gene expression. Hypertension (1997) 0.88
Diltiazem protects the isolated rabbit heart from the mechanical and ultrastructural damage produced by transient hypoxia, low-flow ischemia and exposure to Ca++-free medium. J Pharmacol Exp Ther (1983) 0.87
Hemodynamic and myocardial effects of (-)-delta9-trans-tetrahydrocannabinol in anesthetized dogs. Eur J Pharmacol (1973) 0.87
RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release. J Lipid Mediat (1992) 0.87
The contribution of guanylate cyclase stimulation and K+ channel opening to nicorandil-induced vasorelaxation depends on the conduit vessel and on the nature of the spasmogen. J Pharmacol Exp Ther (1994) 0.87
Endothelin--a new family of endothelium-derived peptides with widespread biological properties. Life Sci (1989) 0.87
Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sci (1990) 0.86
Vascular beta-adrenoceptor stimulating properties of phenylephrine. Eur J Pharmacol (1977) 0.86
Influence of depolarization on vasorelaxant potency and efficacy of Ca2+ entry blockers, K+ channel openers, nitrate derivatives, salbutamol and papaverine in rat aortic rings. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.85
Changes in anatomy, glomerular filtration, and solute excretion in aging rat kidney. Am J Physiol (1985) 0.85
RP 58866 and its active enantiomer RP 62719 (terikalant): blockers of the inward rectifier K+ current acting as pure class III antiarrhythmic agents. J Cardiovasc Pharmacol (1992) 0.84
Increase in plasma renin activity evoked by fenoldopam in dogs is directly mediated by dopamine1 receptor stimulation. J Cardiovasc Pharmacol (1989) 0.84
Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor stimulant properties of cirazoline (LD 3098), a potent alpha-1 adrenoceptor agonist in dogs and rats. J Pharmacol Exp Ther (1982) 0.84
Regional distribution and pharmacological characterization of [125I]endothelin-1 binding sites in human fetal placental vessels. Placenta (1991) 0.84
Inhibition of platelet adhesion to fibrin(ogen) in flowing whole blood by Arg-Gly-Asp and fibrinogen gamma-chain carboxy terminal peptides. Thromb Haemost (1992) 0.84
Effects of Ca2+ antagonists and K+-channel activators on K+-induced contractions in the rat aorta. J Auton Pharmacol (1989) 0.84
Differential inhibition of vascular smooth muscle responses to alpha 1- and alpha 2-adrenoceptor agonists by diltiazem and verapamil. Circ Res (1983) 0.84
Effects of clonidine, prazosin and phentolamine on heart rate and coronary sinus catecholamine concentration during cardioaccelerator nerve stimulation in spinal dogs. Br J Pharmacol (1979) 0.83
Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. Am J Physiol (1997) 0.83
Longitudinal study of solute excretion and glomerular ultrastructure in an experimental model of aging rats free of kidney disease. Lab Invest (1991) 0.83
Osmotic water permeability and solute reflection coefficients of rat kidney brush-border membrane vesicles. Biochim Biophys Acta (1986) 0.83
Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats. J Pharmacol Exp Ther (1991) 0.82
The blood pressure lowering effects of intravenous versus intracerebroventricular prazosin in anaesthetised cats. Eur J Pharmacol (1978) 0.82
Certain observations on interrelationships between respiratory and cardiovascular effects of (-)- 9 -trans-tetrahydrocannabinol. Res Commun Chem Pathol Pharmacol (1972) 0.82
Activation of cardiac KATP channels: an endogenous protective mechanism during repetitive ischemia. Am J Physiol (1993) 0.82
SK&F 87516, a close analog of fenoldopam, is a partial agonist at dopamine-1 and alpha-2 receptors and produces stimulation of 5-hydroxytryptamine-2 receptors in the cardiovascular system of the rat. J Pharmacol Exp Ther (1991) 0.82
Characterization of NK1 and NK2 tachykinin receptors in guinea-pig and rat bronchopulmonary and vascular systems. Br J Pharmacol (1994) 0.81
Heart rate lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of central dopamine receptors leading to inhibition of sympathetic tone and enhancement of parasympathetic outflow. J Pharmacol Exp Ther (1981) 0.81
PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets. Biochem Pharmacol (1987) 0.81
Contractile responses to calcium chloride in rat aortic rings bathed in K+-free solution are resistant to organic calcium antagonists. Br J Pharmacol (1989) 0.81
Role of the sympathetic nervous system in blood pressure maintenance and in the antihypertensive effects of calcium antagonists in spontaneously hypertensive rats. Hypertension (1988) 0.81
Effects of angiotensin II on intracellular calcium and electrical function of mouse renal juxtaglomerular cells. Kidney Int Suppl (1990) 0.81
Influence of pentobarbital anesthesia on the effects of certain autonomic blocking agents on heart rate. Eur J Pharmacol (1973) 0.81
[3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes. J Pharmacol Exp Ther (1988) 0.81
Comparison of mianserin with desipramine, maprotiline and phentolamine on cardiac presynaptic and vascular postsynaptic alpha-adrenoceptors and noradrenaline reuptake in pithed normotensive rats. Br J Pharmacol (1980) 0.81
Comparison of cardiovascular actions of dihydralazine, phentolamine, and prazosin in spontaneously hypertensive rats. J Cardiovasc Pharmacol (1980) 0.80
Endothelins inhibit cyclic-AMP induced renin gene expression in cultured mouse juxtaglomerular cells. Kidney Int (1996) 0.80
Evidence for the existence and ionic modulation of platelet-activating factor receptors mediating degranulatory responses in human polymorphonuclear leukocytes. J Pharmacol Exp Ther (1989) 0.80
Amiloride enhances the secretion but not the synthesis of renin in renal juxtaglomerular cells. Pflugers Arch (1991) 0.80
Blood pressure lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of peripheral dopamine receptors leading to inhibition of sympathetic vascular tone. J Pharmacol Exp Ther (1981) 0.80
Endothelin-1 binding sites and immunoreactivity in the cultured human placental trophoblast: evidence for an autocrine and paracrine role for endothelin-1. J Cardiovasc Pharmacol (1993) 0.80
Biochemical characterization and autoradiographic localization of [125I]endothelin-1 binding sites on trophoblast and blood vessels of human placenta. J Clin Endocrinol Metab (1993) 0.80
Regulation of erythropoietin production. Contrib Nephrol (1988) 0.80
Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. Basic Res Cardiol (1998) 0.80
Cholesterol content and water and solute permeabilities of kidney membranes from aging rats. Am J Physiol (1987) 0.80
Cross tachyphylaxis to endothelin isopeptide-induced hypotension: a phenomenon not seen with proendothelin. Br J Pharmacol (1991) 0.79
Time-dependent fading of the activation of KATP channels, induced by aprikalim and nucleotides, in excised membrane patches from cardiac myocytes. Br J Pharmacol (1995) 0.79
Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part II: Sites and mechanisms of action of dopamine receptor agonists. Life Sci (1982) 0.79
Sleeping times evoked by alpha adrenoceptor agonists in two-day-old chicks: an experimental model to evaluate full and partial agonists at central alpha-2 adrenoceptors. J Pharmacol Exp Ther (1983) 0.79
Studies on the mechanisms of the development of tolerance to the hypotensive effects of fenoldopam in rats. J Cardiovasc Pharmacol (1988) 0.79
Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets. J Pharmacol Exp Ther (1990) 0.79
Intervessel (arteries and veins) and heart/vessel selectivities of therapeutically used calcium entry blockers: variable, vessel-dependent indexes. J Pharmacol Exp Ther (1995) 0.79
Effects of clonidine on canine cardiac neuroeffector structures controlling heart rate. Br J Pharmacol (1980) 0.79
Studies on the hypotensive activity of (-)-delta9-trans-tetrahydrocannabinol in anesthetized dogs. Res Commun Chem Pathol Pharmacol (1973) 0.79
Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats. J Pharmacol Exp Ther (1984) 0.78
Regulation of human renin secretion and renin transcription by quantitative PCR in cultured chorionic cells: synergistic effect of cyclic AMP and protein kinase C. Biochem Biophys Res Commun (1993) 0.78
The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes. J Pharmacol Exp Ther (1991) 0.78
Effects of mianserin on noradrenaline uptake, cardiac presynaptic and vascular postsynaptic alpha-adrenoceptors in rats [proceedings]. Br J Pharmacol (1979) 0.78
The effect of (minus)-delta 9-trans-tetrahydrocannibinol on myocardial contractility and venous return in anesthetized dogs. Eur J Pharmacol (1974) 0.78
Mechanism of antihypertensive activity of orally administered prazosin in spontaneously hypertensive rats. J Cardiovasc Pharmacol (1980) 0.78
Role of adrenocortical hormones on the ontogenesis of ventricular action potential of rat myocardium. J Mol Cell Cardiol (1981) 0.78